. . . . . . . "[The best described of these are mutations in Fms-like tyrosine kinase 3, nucleophosmin 1, and CCAAT enhancer-binding protein-alpha in those with cytogenetically AML, which allow more accurate risk stratification and help better 'target' patients who may benefit from allogeneic transplantation (specifically those with activating FLT3 mutation).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:11:30+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .